Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [18F]FDG-positive metastatic neuroendocrine tumors
Our results show PRRT combined with CAPTEM as the most promising regimen, achieving higher response rates in [¹⁸F]FDG-positive mNETs compared with PRRT alone or PRRT plus TEM. Further studies are required to confirm its added value in terms of survival outcomes. No increased toxicity seems to be associated with combination therapy compared to PRRT alone.
Authors
- Gianpaolo di Santo
- Irene Johanna Virgolini (ORCID: https://orcid.org/0000-0001-7097-6170)
- Giulia Santo (ORCID: https://orcid.org/0000-0001-6565-0686)
- Angela Djanani (ORCID: https://orcid.org/0000-0002-2997-5157)
- Günther Gastl
- Lukas Wirth
- Ariane Kronthaler (ORCID: https://orcid.org/0009-0007-9442-6158)
Institutions
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- Magna Graecia University (IT)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1007/s00259-025-07606-3
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.35